MA42290B1 - Gel fluide ophtalmique de bimatoprost - Google Patents

Gel fluide ophtalmique de bimatoprost

Info

Publication number
MA42290B1
MA42290B1 MA42290A MA42290A MA42290B1 MA 42290 B1 MA42290 B1 MA 42290B1 MA 42290 A MA42290 A MA 42290A MA 42290 A MA42290 A MA 42290A MA 42290 B1 MA42290 B1 MA 42290B1
Authority
MA
Morocco
Prior art keywords
amount
weight
bimatoprost
ophthalmic
viscosity
Prior art date
Application number
MA42290A
Other languages
English (en)
Other versions
MA42290A (fr
Inventor
Heinz Polzer
Pierre-Paul Elena
Jürgen Senge
Original Assignee
Medproject Pharma Enwicklungs Und Vertriebsgesellschaft Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medproject Pharma Enwicklungs Und Vertriebsgesellschaft Mbh filed Critical Medproject Pharma Enwicklungs Und Vertriebsgesellschaft Mbh
Publication of MA42290A publication Critical patent/MA42290A/fr
Publication of MA42290B1 publication Critical patent/MA42290B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Abstract

L'invention concerne un gel ophtalmique administrable sous forme de gouttes, ledit gel ayant une composition comprenant du bimatoprost en une quantité comprise entre 0,003 et 0,03 % en poids, du polyacrylate en une quantité > 0,2 % en poids, de la polyvidone (pvp), du dextrane, des polyéthylène glycols (peg), de la carboxyméthyl cellulose (cmc) ou de l'alcool polyvinylique (pva) en une quantité comprise entre 0,2 et 10 % en poids, un agent d'isotonisation en une quantité permettant d'atteindre une osmolalité comprise entre 200 et 400 mosml/kg, un sel pour régler la viscosité en une quantité comprise entre 0,05 et 0,4 % en poids, une base en une quantité permettant de régler le ph compris entre 6 et 8 et des excipients normalement utilisés dans des gels ophtalmiques, à une viscosité se situant dans la plage comprise entre 200 et 2 000 mpa·s.
MA42290A 2015-06-09 2016-06-08 Gel fluide ophtalmique de bimatoprost MA42290B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15171233.8A EP3103439B1 (fr) 2015-06-09 2015-06-09 Gel ophtalmique de bimatoprost applicable en gouttes
PCT/EP2016/062990 WO2016198434A1 (fr) 2015-06-09 2016-06-08 Gel ophthalmique à base de bimatoprost administrable sous forme de gouttes
EP16729525.2A EP3307241B8 (fr) 2015-06-09 2016-06-08 Gel fluide ophtalmique de bimatoprost

Publications (2)

Publication Number Publication Date
MA42290A MA42290A (fr) 2016-12-15
MA42290B1 true MA42290B1 (fr) 2018-11-30

Family

ID=53298285

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42290A MA42290B1 (fr) 2015-06-09 2016-06-08 Gel fluide ophtalmique de bimatoprost

Country Status (28)

Country Link
US (1) US10314780B2 (fr)
EP (2) EP3103439B1 (fr)
JP (1) JP6342087B1 (fr)
KR (1) KR101889878B1 (fr)
CN (1) CN107771074B (fr)
AU (1) AU2016277336B2 (fr)
BR (1) BR112017026552B1 (fr)
CA (1) CA2985897C (fr)
CY (1) CY1120883T1 (fr)
DK (1) DK3307241T3 (fr)
ES (2) ES2747302T3 (fr)
HK (1) HK1247118A1 (fr)
HR (1) HRP20181840T1 (fr)
IL (1) IL256071B (fr)
LT (1) LT3307241T (fr)
MA (1) MA42290B1 (fr)
MX (1) MX2017015835A (fr)
PL (2) PL3103439T3 (fr)
PT (1) PT3307241T (fr)
RS (1) RS57948B1 (fr)
RU (1) RU2698456C2 (fr)
SA (1) SA517390480B1 (fr)
SG (1) SG11201708642VA (fr)
SI (1) SI3307241T1 (fr)
TN (1) TN2017000445A1 (fr)
TR (1) TR201815791T4 (fr)
UA (1) UA121139C2 (fr)
WO (1) WO2016198434A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112566622A (zh) * 2018-06-19 2021-03-26 细胞疗法有限责任公司 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统
CN110200904B (zh) * 2019-05-27 2021-07-23 上海昊海生物科技股份有限公司 一种降眼压缓释滴眼组合物及其制备方法
US11786538B2 (en) * 2019-12-11 2023-10-17 Somerset Therapeutics, Llc Low benzalkonium chloride bimatoprost ophthalmic compositions with effective penetration and preservation properties

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4209722C3 (de) 1992-03-25 1997-06-19 Medproject Pharma Entwicklungs Tropfbares Gel für die Augenheilkunde
DE10132876A1 (de) * 2001-07-06 2003-01-30 Medproject Pharma Entwicklungs Zweiphasige, tropfbare Hydrogele zur Anwendung am Auge
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
EP2127638A1 (fr) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Procédé et composition pour traiter l'hypertension oculaire et le glaucome
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
WO2012015996A2 (fr) 2010-07-29 2012-02-02 Allergan, Inc. Solutions de bimatoprost sans conservateur
WO2012163827A2 (fr) * 2011-05-27 2012-12-06 Ratiopharm Gmbh Préparation ophtalmique contenant un analogue de pgf2alpha
BR112014001118A2 (pt) * 2011-07-20 2017-02-14 Allergan Inc combinação tópica para aplicação oftálmica e uso de bimatoprost e brimonidina
CN104288092A (zh) * 2013-07-16 2015-01-21 广东东阳光药业有限公司 拉坦前列素滴眼剂
CN104622798B (zh) * 2014-12-05 2017-12-22 广东东阳光药业有限公司 一种含有他氟前列素的滴眼液及其制备方法

Also Published As

Publication number Publication date
PT3307241T (pt) 2018-11-26
MA42290A (fr) 2016-12-15
DK3307241T3 (en) 2018-11-05
LT3307241T (lt) 2018-12-10
AU2016277336B2 (en) 2018-12-06
KR101889878B1 (ko) 2018-08-20
RU2017138099A3 (fr) 2019-07-17
EP3307241A1 (fr) 2018-04-18
CN107771074B (zh) 2021-04-02
UA121139C2 (uk) 2020-04-10
CA2985897A1 (fr) 2016-12-15
WO2016198434A1 (fr) 2016-12-15
BR112017026552B1 (pt) 2023-11-14
ES2703432T3 (es) 2019-03-08
SA517390480B1 (ar) 2021-03-11
SI3307241T1 (sl) 2018-12-31
TR201815791T4 (tr) 2018-11-21
BR112017026552A2 (pt) 2018-08-14
RU2017138099A (ru) 2019-07-10
EP3307241B8 (fr) 2018-12-19
KR20170140301A (ko) 2017-12-20
HRP20181840T1 (hr) 2019-01-11
RS57948B1 (sr) 2019-01-31
MX2017015835A (es) 2018-08-15
EP3103439A1 (fr) 2016-12-14
TN2017000445A1 (en) 2019-04-12
RU2698456C2 (ru) 2019-08-27
IL256071A (en) 2018-01-31
JP2018518466A (ja) 2018-07-12
ES2747302T3 (es) 2020-03-10
PL3307241T3 (pl) 2019-03-29
EP3103439B1 (fr) 2019-08-07
IL256071B (en) 2019-09-26
PL3103439T3 (pl) 2019-12-31
US20180228724A1 (en) 2018-08-16
CY1120883T1 (el) 2019-12-11
JP6342087B1 (ja) 2018-06-13
CA2985897C (fr) 2019-10-01
AU2016277336A1 (en) 2017-11-23
US10314780B2 (en) 2019-06-11
CN107771074A (zh) 2018-03-06
EP3307241B1 (fr) 2018-09-26
HK1247118A1 (zh) 2018-09-21
SG11201708642VA (en) 2017-11-29

Similar Documents

Publication Publication Date Title
MA42290B1 (fr) Gel fluide ophtalmique de bimatoprost
EP4218832A3 (fr) Méthodes et compositions pour radiomarquage au 18f du domaine de fibronectine iii
WO2018062866A3 (fr) Protéine recombinante cas9 perméable aux cellules (cp) et ses utilisations
MX2022011896A (es) Composiciones oftalmicas.
MA33767B1 (fr) Nouvelle utilisation anticancéreuse du cabazitaxel
MA49673B1 (fr) Combinaison comprenant du palbociclib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique et sa utilisation pour le traitement du cancer
FR3029785B1 (fr) Dispersions stables comprenant des gouttes d'agent parfumant
MX2021002935A (es) Formulacion de anticuerpos contra csf-1r.
WO2017223261A3 (fr) Hydrogels, articles comprenant des hydrogels, et procédés associés
WO2014186750A3 (fr) Variants de tnfsf15 et dcr3 associés à la maladie de crohn
MA46548A (fr) Fsh pour le traitement de l'infertilité
MA53927B1 (fr) Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel
EA202192786A1 (ru) Твердые формы (e)-3-[2-(2-тиенил)винил]-1h-пиразола
EP4293116A3 (fr) Fibrinogène liquide stable
MA39286A (fr) Formes cristallines d'inhibiteurs de la tyrosine kinase et leurs sels
JP2018536659A5 (ja) 白内障および老視の抑制に用いられるｐｅｇを含有する二官能性分子を含む眼科用組成物
FR3042502B1 (fr) Copolymeres fluores fonctionnalises
FR3078826B1 (fr) Photodiode verticale
WO2014097258A3 (fr) Composition cosmétique aqueuse comprenant une alkylcellulose
FR3051671B1 (fr) Cosmetiques correcteurs d'imperfections
IT201700061233A1 (it) Ammortizzatore idraulico per sospensione di veicolo provvisto di tampone idraulico operante durante la corsa di compressione dell'ammortizzatore.
FR3045343B1 (fr) Composition oxydante comprenant au moins 30% de tensioactifs
MX2023007036A (es) Formulaciones de liberacion prolongada para aplicaciones intra-articulares.
EA202091948A1 (ru) Ручное домкратное/выравнивающее приспособление
JP2018045476A5 (fr)